Take-Home Messages of the Major Clinical Trials in Mechanical Circulatory Support

John P. Skendelas; Daniel J. Goldstein

doi:10.1002/9781119633884.ch46

Take-Home Messages of the Major Clinical Trials in Mechanical Circulatory Support

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Durable mechanical circulatory support (MCS) devices were born from a need to temporize and bridge patients with advanced heart failure (HF) to await transplant. This chapter aims to chronologically explore the devices, salient features, outcomes, and ultimate impact of the landmark MCS clinical trials that have shaped the field of durable, life-extending, quality-of-life-enhancing mechanical support. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial was launched in the 1990s as a reaction to the growing epidemic of advanced HF and ongoing lack of available donor hearts. The REMATCH trial highlighted the limitations of pulsatile left ventricular assist system technology and spawned interest in the development of smaller devices that, by necessity, would require transitioning to a nonpulsatile mode of blood flow.

Original language	English (US)
Title of host publication	Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease
Publisher	wiley
Pages	639-652
Number of pages	14
ISBN (Electronic)	9781119633884
ISBN (Print)	9781119633846
DOIs	https://doi.org/10.1002/9781119633884.ch46
State	Published - Jan 1 2023

Keywords

REMATCH trial
blood flow
heart failure
left ventricular assist system
mechanical circulatory support devices

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781119633884.ch46

Cite this

@inbook{2311580242e947268a8ecc185a0d34a4,

title = "Take-Home Messages of the Major Clinical Trials in Mechanical Circulatory Support",

abstract = "Durable mechanical circulatory support (MCS) devices were born from a need to temporize and bridge patients with advanced heart failure (HF) to await transplant. This chapter aims to chronologically explore the devices, salient features, outcomes, and ultimate impact of the landmark MCS clinical trials that have shaped the field of durable, life-extending, quality-of-life-enhancing mechanical support. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial was launched in the 1990s as a reaction to the growing epidemic of advanced HF and ongoing lack of available donor hearts. The REMATCH trial highlighted the limitations of pulsatile left ventricular assist system technology and spawned interest in the development of smaller devices that, by necessity, would require transitioning to a nonpulsatile mode of blood flow.",

keywords = "REMATCH trial, blood flow, heart failure, left ventricular assist system, mechanical circulatory support devices",

author = "Skendelas, {John P.} and Goldstein, {Daniel J.}",

note = "Publisher Copyright: {\textcopyright} 2024 John Wiley & Sons Ltd.",

year = "2023",

month = jan,

day = "1",

doi = "10.1002/9781119633884.ch46",

language = "English (US)",

isbn = "9781119633846",

pages = "639--652",

booktitle = "Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease",

publisher = "wiley",

}

TY - CHAP

T1 - Take-Home Messages of the Major Clinical Trials in Mechanical Circulatory Support

AU - Skendelas, John P.

AU - Goldstein, Daniel J.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Durable mechanical circulatory support (MCS) devices were born from a need to temporize and bridge patients with advanced heart failure (HF) to await transplant. This chapter aims to chronologically explore the devices, salient features, outcomes, and ultimate impact of the landmark MCS clinical trials that have shaped the field of durable, life-extending, quality-of-life-enhancing mechanical support. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial was launched in the 1990s as a reaction to the growing epidemic of advanced HF and ongoing lack of available donor hearts. The REMATCH trial highlighted the limitations of pulsatile left ventricular assist system technology and spawned interest in the development of smaller devices that, by necessity, would require transitioning to a nonpulsatile mode of blood flow.

AB - Durable mechanical circulatory support (MCS) devices were born from a need to temporize and bridge patients with advanced heart failure (HF) to await transplant. This chapter aims to chronologically explore the devices, salient features, outcomes, and ultimate impact of the landmark MCS clinical trials that have shaped the field of durable, life-extending, quality-of-life-enhancing mechanical support. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial was launched in the 1990s as a reaction to the growing epidemic of advanced HF and ongoing lack of available donor hearts. The REMATCH trial highlighted the limitations of pulsatile left ventricular assist system technology and spawned interest in the development of smaller devices that, by necessity, would require transitioning to a nonpulsatile mode of blood flow.

KW - REMATCH trial

KW - blood flow

KW - heart failure

KW - left ventricular assist system

KW - mechanical circulatory support devices

UR - http://www.scopus.com/inward/record.url?scp=85174088963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85174088963&partnerID=8YFLogxK

U2 - 10.1002/9781119633884.ch46

DO - 10.1002/9781119633884.ch46

M3 - Chapter

AN - SCOPUS:85174088963

SN - 9781119633846

SP - 639

EP - 652

BT - Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease

PB - wiley

ER -

Take-Home Messages of the Major Clinical Trials in Mechanical Circulatory Support

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this